Method for treating neurotrauma

Patent metadata

Field	Value
Publication number	US-9579336-B2
Application number	US-201214005098-A
Country	US
Kind code	B2
Filing date	Mar 14, 2012
Priority date	Mar 14, 2011
Publication date	Feb 28, 2017
Grant date	Feb 28, 2017

Abstract

The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of □-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

First claim

The invention claimed is:

1. A method for treating spinal cord injury in a subject in need thereof, the method comprising administering to the subject a composition comprising:
(i) one or more of uridine, cytidine, or salts, or esters thereof;
(ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of α-linolenic acid (ALA), calculated on the weight of all fatty acids;
(iii) choline, or salts or esters thereof; and
(iv) at least one B complex vitamin.

2. The method according to claim 1 , wherein the composition comprises (i) one or more uridine, cytidine, or phosphates thereof.

3. The method according to claim 1 , wherein the lipid fraction comprises medium chain fatty acids, wherein the sum of medium chain fatty acids C6:0+C7:0+C8:0 over the sum of C9:0 and C10:0 is less than 2:1.

4. The method according to claim 1 , wherein the lipid fraction comprises less than 2 weight % fatty acids of less than 14 carbon atoms, based on total fatty acids.

5. The method according to claim 1 , wherein the composition further comprises less than 25 mg of the sum of cysteine and taurine per 100 ml of the composition.

6. The method according to claim 1 , wherein the composition further comprises linoleic acid (LA) in an amount of less than 15 g/100 g fatty acids.

7. The method according to claim 1 , wherein the B complex vitamin is selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

8. The method according to claim 7 , wherein the B complex vitamin comprises vitamin B6, B9 and B12.

9. The method according to claim 1 , wherein the lipid fraction comprises 9 to 300 mg/100 kJ DHA+EPA+DPA.

10. The method according to claim 1 , wherein the lipid fraction comprises 9 to 300 mg/100 kJ DHA+EPA.

11. The method according to claim 1 , wherein the composition comprises 1.5 to 130 mg/100 kJ of one or more of uridine, cytidine, or phosphates thereof, calculated as uridine and cytidine.

12. The method according to claim 1 , wherein the composition comprises 1 to 300 mg/100 kJ of choline, or salts or esters thereof, calculated as choline.

13. The method according to claim 1 , wherein the composition further comprises one or more selected from the group consisting of vitamin C, vitamin E, and selenium.

14. The method according to claim 1 , wherein the composition further comprises at least one phospholipid.

15. The method according to claim 1 , wherein the composition is a nutritional product.

16. The method according to claim 1 , wherein the composition comprises, per 100 ml of liquid:
100-500 mg EPA,
1000-1500 mg DHA,
80-600 mg phospholipids,
200-600 mg choline,
400-800 mg uridine monophosphate (UMP),
20-60 mg alpha-TE (vitamin E),
60-100 mg vitamin C,
40-80 μg selenium,
1-5 μg vitamin B12,
0.5-2 mg vitamin B6, and
200-600 μg folic acid.

17. A method for treating spinal cord injury in a subject in need thereof, the method comprising administering to the subject a kit of parts comprising:
i) one or more of uridine, cytidine, or salts thereof;
ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), in which the lipid fraction comprises less than 2 weight % of α-linolenic acid (ALA), calculated on the weight of all fatty acids;
iii) choline, or salts or esters thereof;
the kit further comprising at least one B complex vitamin.

18. The method according to claim 17 , wherein said kit comprises (i) one or more of uridine, cytidine, or phosphates thereof.

19. The method according to claim 1 , wherein the composition comprises:
(i) uridine monophosphate;
(ii) a lipid fraction comprising EPA and DHA, in which the lipid fraction comprises less than 2 weight % of α-linolenic acid (ALA), calculated on the weight of all fatty acids;
(iii) choline, or salts or esters thereof; and
(iv) at least one B complex vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

Assignees

• De Wilde Mattheus Cornelis
• Sijben Johannes Wilhelmus Christina
• Kamphuis Patrick Joseph Gerardus Hendrikus
• Hageman Robert Johan Joseph
• Nutricia Nv

Inventors

• De Wilde Mattheus Cornelis
• Sijben Johannes Wilhelmus Christina
• Kamphuis Patrick Joseph Gerardus Hendrikus
• Hageman Robert Johan Joseph

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title